These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 38725854)

  • 21. An Effective Epigenetic-PARP Inhibitor Combination Therapy for Breast and Ovarian Cancers Independent of BRCA Mutations.
    Pulliam N; Fang F; Ozes AR; Tang J; Adewuyi A; Keer H; Lyons J; Baylin SB; Matei D; Nakshatri H; Rassool FV; Miller KD; Nephew KP
    Clin Cancer Res; 2018 Jul; 24(13):3163-3175. PubMed ID: 29615458
    [No Abstract]   [Full Text] [Related]  

  • 22. HMGB3 promotes PARP inhibitor resistance through interacting with PARP1 in ovarian cancer.
    Ma H; Qi G; Han F; Lu W; Peng J; Li R; Yan S; Yuan C; Kong B
    Cell Death Dis; 2022 Mar; 13(3):263. PubMed ID: 35332131
    [TBL] [Abstract][Full Text] [Related]  

  • 23. FLT1 activation in cancer cells promotes PARP-inhibitor resistance in breast cancer.
    Tai Y; Chow A; Han S; Coker C; Ma W; Gu Y; Estrada Navarro V; Kandpal M; Hibshoosh H; Kalinsky K; Manova-Todorova K; Safonov A; Walsh EM; Robson M; Norton L; Baer R; Merghoub T; Biswas AK; Acharyya S
    EMBO Mol Med; 2024 Aug; 16(8):1957-1980. PubMed ID: 38956205
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Therapeutic applications of PARP inhibitors in ovarian cancer.
    Xie H; Wang W; Xia B; Jin W; Lou G
    Biomed Pharmacother; 2020 Jul; 127():110204. PubMed ID: 32422564
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Heterogeneity and Clonal Evolution of Acquired PARP Inhibitor Resistance in
    Färkkilä A; Rodríguez A; Oikkonen J; Gulhan DC; Nguyen H; Domínguez J; Ramos S; Mills CE; Pérez-Villatoro F; Lazaro JB; Zhou J; Clairmont CS; Moreau LA; Park PJ; Sorger PK; Hautaniemi S; Frias S; D'Andrea AD
    Cancer Res; 2021 May; 81(10):2774-2787. PubMed ID: 33514515
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inhibitory effects of Paris saponin I, II, Ⅵ and Ⅶ on HUVEC cells through regulation of VEGFR2, PI3K/AKT/mTOR, Src/eNOS, PLCγ/ERK/MERK, and JAK2-STAT3 pathways.
    Wang W; Liu Y; You L; Sun M; Qu C; Dong X; Yin X; Ni J
    Biomed Pharmacother; 2020 Nov; 131():110750. PubMed ID: 32942160
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Histone methyltransferases EHMT1 and EHMT2 (GLP/G9A) maintain PARP inhibitor resistance in high-grade serous ovarian carcinoma.
    Watson ZL; Yamamoto TM; McMellen A; Kim H; Hughes CJ; Wheeler LJ; Post MD; Behbakht K; Bitler BG
    Clin Epigenetics; 2019 Nov; 11(1):165. PubMed ID: 31775874
    [TBL] [Abstract][Full Text] [Related]  

  • 28. PARP inhibitor resistance in ovarian cancer: Underlying mechanisms and therapeutic approaches targeting the ATR/CHK1 pathway.
    Biegała Ł; Gajek A; Marczak A; Rogalska A
    Biochim Biophys Acta Rev Cancer; 2021 Dec; 1876(2):188633. PubMed ID: 34619333
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The disruption of the CCDC6 - PP4 axis induces a BRCAness like phenotype and sensitivity to PARP inhibitors in high-grade serous ovarian carcinoma.
    Morra F; Merolla F; Damia G; Ricci F; Varricchio S; Ilardi G; Arenare L; Califano D; Napolitano V; Fruscio R; Melillo RM; Palazzo L; Celetti A
    J Exp Clin Cancer Res; 2022 Aug; 41(1):245. PubMed ID: 35964058
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combination of Niraparib, Cisplatin and Twist Knockdown in Cisplatin-Resistant Ovarian Cancer Cells Potentially Enhances Synthetic Lethality through ER-Stress Mediated Mitochondrial Apoptosis Pathway.
    Bahar E; Kim JY; Kim DC; Kim HS; Yoon H
    Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33920140
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Blockade of the lncRNA-PART1-PHB2 axis confers resistance to PARP inhibitor and promotes cellular senescence in ovarian cancer.
    Wu H; Sun C; Cao W; Teng Q; Ma X; Schiöth HB; Dong R; Zhang Q; Kong B
    Cancer Lett; 2024 Oct; 602():217192. PubMed ID: 39181433
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Poly(adenosine diphosphate ribose) polymerase inhibitors induce autophagy-mediated drug resistance in ovarian cancer cells, xenografts, and patient-derived xenograft models.
    Santiago-O'Farrill JM; Weroha SJ; Hou X; Oberg AL; Heinzen EP; Maurer MJ; Pang L; Rask P; Amaravadi RK; Becker SE; Romero I; Rubio MJ; Matias-Guiu X; Santacana M; Llombart-Cussac A; Poveda A; Lu Z; Bast RC
    Cancer; 2020 Feb; 126(4):894-907. PubMed ID: 31714594
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inhibition of nicotinamide dinucleotide salvage pathway counters acquired and intrinsic poly(ADP-ribose) polymerase inhibitor resistance in high-grade serous ovarian cancer.
    Sauriol SA; Carmona E; Udaskin ML; Radulovich N; Leclerc-Desaulniers K; Rottapel R; Oza AM; Lheureux S; Provencher DM; Mes-Masson AM
    Sci Rep; 2023 Feb; 13(1):3334. PubMed ID: 36849518
    [TBL] [Abstract][Full Text] [Related]  

  • 34. N
    Fukumoto T; Zhu H; Nacarelli T; Karakashev S; Fatkhutdinov N; Wu S; Liu P; Kossenkov AV; Showe LC; Jean S; Zhang L; Zhang R
    Cancer Res; 2019 Jun; 79(11):2812-2820. PubMed ID: 30967398
    [TBL] [Abstract][Full Text] [Related]  

  • 35. C/EBPβ promotes poly(ADP-ribose) polymerase inhibitor resistance by enhancing homologous recombination repair in high-grade serous ovarian cancer.
    Tan J; Zheng X; Li M; Ye F; Song C; Xu C; Zhang X; Li W; Wang Y; Zeng S; Li H; Chen G; Huang X; Ma D; Liu D; Gao Q
    Oncogene; 2021 Jun; 40(22):3845-3858. PubMed ID: 33966038
    [TBL] [Abstract][Full Text] [Related]  

  • 36. RAD51D Secondary Mutation-Mediated Resistance to PARP-Inhibitor-Based Therapy in HGSOC.
    Xu J; Dai Y; Gao Y; Chai R; Lu C; Yu B; Kang Y; Xu C
    Int J Mol Sci; 2023 Sep; 24(19):. PubMed ID: 37833926
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sequential Targeting of PLK1 and PARP1 Reverses the Resistance to PARP Inhibitors and Enhances Platin-Based Chemotherapy in BRCA-Deficient High-Grade Serous Ovarian Cancer with KRAS Amplification.
    Gasimli K; Raab M; Tahmasbi Rad M; Kurunci-Csacsko E; Becker S; Strebhardt K; Sanhaji M
    Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142803
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Developing patient-derived organoids to predict PARP inhibitor response and explore resistance overcoming strategies in ovarian cancer.
    Tao M; Sun F; Wang J; Wang Y; Zhu H; Chen M; Liu L; Liu L; Lin H; Wu X
    Pharmacol Res; 2022 May; 179():106232. PubMed ID: 35462012
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Clinical Challenges, Trials, and Errors of Combatting Poly(ADP-Ribose) Polymerase Inhibitors Resistance.
    Pham MM; Hinchcliff E; Avila M; Westin SN
    Cancer J; 2021 Nov-Dec 01; 27(6):491-500. PubMed ID: 34904812
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Resistance to Poly (ADP-Ribose) Polymerase Inhibitors (PARPi): Mechanisms and Potential to Reverse.
    Washington CR; Moore KN
    Curr Oncol Rep; 2022 Dec; 24(12):1685-1693. PubMed ID: 36346509
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.